It's a good time to be a shareholder in Alliance Pharma (LON:APH): as the share approaches its 52-week high, holders may be wondering whether to sell and take the profit, or buy more and ride the uptrend. Shares in Alliance Pharma are...
APH — Alliance Pharma Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedMid CapHigh Flyer
- £600.66m
- £709.76m
- £129.80m
- 73
- 37
- 94
- 79
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.44 | ||
| PEG Ratio (f) | 1.97 | ||
| EPS Growth (f) | 9.72% | ||
| Dividend Yield (f) | 1.49% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.14 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 18.53 | ||
| Price to Sales | 4.09 | ||
| EV to EBITDA | 16.92 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.89% | ||
| Return on Equity | 6.52% | ||
| Operating Margin | 22.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 97.49 | 101.64 | 118.21 | 135.64 | 129.8 | 167.47 | 184.27 | 21.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +35.94 | +28.93 | -2.03 | +7.34 | -17.09 | +35.84 | +9.72 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for APH
Shares in Alliance Pharma (LON:APH) are currently trading close to a 52 week high, with the share price up by around 5.17% to 103.8p over the past week. On a one-month basis, the Alliance Pharma price has risen by 4.32%. For investors...
Shares in Alliance Pharma (LON:APH) are currently trading close to a 52 week high, with the share price up by around 2.40% to 98.1p over the past week. On a one-month basis, the Alliance Pharma price has risen by 2.72%. For investors h...
Shares in Alliance Pharma (LON:APH) are currently trading close to a 52 week high, with the share price up by around 2.78% - to 95.772 - over the past week. On a one-month basis, the Alliance Pharma share price has risen by 13.5%. For...
It's difficult to pick your own shares successfully – research consistently shows that more than half of retail investors in the UK and US who pick their own shares lose money. Even for skilful investors who buy a share and see it rise...
Profile Summary
Alliance Pharma plc is a United Kingdom-based holding company. The Company is primarily engaged in the acquisition, marketing and distribution of healthcare and pharmaceutical products. It is focused on two areas, which include Consumer Healthcare brands and Prescription Medicines. The Company’s Consumer Healthcare brands include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse and Aloclair. Its Prescription Medicines include Hydromol, Flamma Franchise and Forceval. Its brands also include Ashton & Parsons and Anbesol. The Company’s products include Alliance Calcium Syrup, Amantadine hydrochloride, Aiweidi, Biodermatin, Biotaches, Buccastem M, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Gen-Ongles, Irenat, ISIB, Isocarboxazid, Jonctum, Kelo-Stretch, Lypsyl, Lefuzhi, Malunjunshe, MolluDab, Menadiol, Neostigmine and Nu-Seals. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).
Directors
- David Cook NEC (53)
- Peter Butterfield CEO
- Andrew Franklin CFO
- Stephen Kidner COO
- Janice Timberlake CHO
- Alex Duggan OTH
- Dan Thomas OTH
- Chris Chrysanthou SEC
- Jo Couilliard NID
- Richard Jones NID
- Kristof Neirynck NID
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- June 26th, 2001
- Public Since
- November 22nd, 2001
- No. of Employees
- 221
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 538,225,524
- Address
- Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB
- Web
- https://www.alliancepharmaceuticals.com/
- Phone
- +44 1249466966
- Auditors
- KPMG LLP
Latest News for APH
Upcoming Events for APH
Full Year 2021 Alliance Pharma PLC Earnings Release
Similar to APH
Abcam
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Benchmark Holdings
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
FAQ
What is the Alliance Pharma share price?
As of Today at 06:07 UTC, shares in Alliance Pharma are trading at 111.60p. This share price information is delayed by 15 minutes.
How has the Alliance Pharma share price performed this year?
Shares in Alliance Pharma last closed at 111.60p and the price had moved by +26.82% over the past 365 days. In terms of relative price strength the Alliance Pharma share price has outperformed the FTSE All Share Index by +12.83% over the past year.
What are the analyst and broker recommendations for Alliance Pharma?
The overall consensus recommendation for Alliance Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Alliance Pharma dividend yield?
The Alliance Pharma dividend yield is 1.47% based on the trailing twelve month period.
Does Alliance Pharma pay a dividend?
Last year, Alliance Pharma paid a total dividend of £0.02, and it currently has a trailing dividend yield of 1.47%. We do not have any data on when Alliance Pharma is to next pay dividends.
When does Alliance Pharma next pay dividends?
We do not have data on when Alliance Pharma is to next pay dividends. The historic dividend yield on Alliance Pharma shares is currently 1.47%.
How do I buy Alliance Pharma shares?
To buy shares in Alliance Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alliance Pharma?
As of the previous close price of 111.60p, shares in Alliance Pharma had a market capitalisation of £600.66m.
Where are Alliance Pharma shares listed?
Here are the trading details for Alliance Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: APH
What kind of share is Alliance Pharma?
Based on an overall assessment of its quality, value and momentum Alliance Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alliance Pharma share price forecast for 2022?
The analyst consensus target price for shares in Alliance Pharma is 115.56p. That is 3.55% above the last closing price of 111.60p.
Analysts covering Alliance Pharma currently have a consensus Earnings Per Share (EPS) forecast of £0.06 for the next financial year.
What is the trend in the Alliance Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alliance Pharma. Over the past six months, its share price has outperformed the FTSE All Share Index by +5.13%.
As of the last closing price of 111.60p, shares in Alliance Pharma were trading +9.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alliance Pharma PE Ratio?
The Alliance Pharma PE ratio based on its reported earnings over the past 12 months is 17.44. The shares last closed at 111.60p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alliance Pharma?
Alliance Pharma's management team is headed by:
- David Cook - NEC
- Peter Butterfield - CEO
- Andrew Franklin - CFO
- Stephen Kidner - COO
- Janice Timberlake - CHO
- Alex Duggan - OTH
- Dan Thomas - OTH
- Chris Chrysanthou - SEC
- Jo Couilliard - NID
- Richard Jones - NID
- Kristof Neirynck - NID